natgillin/translations-raw huggingface dataset:
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial 
• bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel 1A Pharma. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden boste vzeli Klopidogrel 1A Pharma.
The benefit of the combination of Clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
Koristnosti zdravljenja s kombinacijo klopidrogela in ASA, ki bi bilo daljše od štirih tednov, v tem okviru niso preučevali (glejte poglavje 5.1).
In TRITON-TIMI 38 and 3 of the cohort studies (n = 3,516; Collet, Sibbing, Giusti), patients with an impaired metaboliser status (intermediate and poor combined) had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers. 
V TRITON-TIMI 38 in 3 kohortnih študijah (n = 3.516; Collet, Sibbing, Giusti) so imeli bolniki s statusom nezadostnega presnavljalca (srednji in slabi presnavljalci skupaj) večji delež kardiovaskularnih dogodkov (smrt, miokardni infarkt, možganska kap) ali tromboze na opornici kot močni metabolizatorji.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between Clopidogrel and placebo was not significantly affected by the concomitant heparin therapy. 
Heparine so uporabljali pri več kot 90 % bolnikov, sočasna uporaba heparinske terapije ni pomembno vplivala na relativni delež krvavitev med klopidogrelom in placebom.
Overall, Clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg/dan, ne glede na starost, spol ali raso.
The pharmacokinetics of the active metabolite of Clopidogrel is not known in these special populations. 
Farmakokinetika aktivnega presnovka klopidogrela v teh posebnih skupinah bolnikov ni znana.
Consequently, NSAIDs including Cox-2 inhibitors and Clopidogrel should be co-administered with caution (see section 4.4). 
Zaradi tega moramo NSAIDs, vključno s COX2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
Thus, beyond 3 months of treatment, the benefit observed in the Clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostala (glejte poglavje 4.4).
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of Clopidogrel. 
Farmakokinetika digoksina ali teofilina nista bili spremenjeni ob sočasni uporabi klopidogrela.
There was no excess in major bleeds with Clopidogrel + ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery (4.4% Clopidogrel+ASA vs. 5.3% placebo+ASA). 
Število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom (4,4 % klopidogrel in ASA proti 5,3 % placebo in ASA).
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel 1A Pharma. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel 1A Pharma.
There may be genetic variants of other CYP450 enzymes with effects on the ability to form the active metabolite of Clopidogrel. 
Mogoče je, da obstajajo tudi genetske različice drugih encimov CYP450, ki vplivajo na zmožnost tvorbe aktivnega presnovka klopidogrela.
CYP2C19 poor metaboliser status is associated with diminished response to Clopidogrel. 
Status slabega presnavljalca s CYP2C19 je povezan z manjšim odzivom na klopidogrel.
If you become pregnant while taking Clopidogrel 1A Pharma, consult your doctor immediately as it is recommended not to take Clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Klopidogrel 1A Pharma zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
Animal studies have shown excretion of Clopidogrel in breast milk. 
Študije na živalih so pokazale, da se klopidogrel izloča v materinem materinem mleku.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, Clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p = 0.639]). 
Pri bolnikih, ki so bili vključeni v preskušanje samo na podlagi nedavnega miokardnega infarkta, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT= --4,0 %; IZ: --22,5 do 11,7 [p=0,639]).
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE 
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4
Elimination Following an oral dose of 14C-labelled Clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
Eliminacija Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for Clopidogrel+ASA, and 6.3% for placebo+ASA. 
Pri bolnikih, ki so ostali na zdravljenju do 5 dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel in ASA in 6,3 % za placebo in ASA.
Acetylsalicylic acid (ASA): ASA did not modify the Clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but Clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation. 
Acetilsalicilna kislina (ASA): ASA ni spremenila s klopidogrelom dosežene inhibicije z ADP-jem sprožene agregacije trombocitov, vendar klopidogrel ojača učinek ASA na s kolagenom sproženo agregacijo trombocitov.
Clopidogrel 1A Pharma is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Zdravilo Klopidogrel 1A Pharma se jemlje za preprečevanje nastanka krvnih strdkov (trombov) v otrdelih krvnih žilah (arterijah), proces je znan kot aterotromboza in lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
A pharmacodynamic interaction between Clopidogrel and heparin is possible, leading to increased risk of bleeding. 
Farmakodinamična interakcija med klopidogrelom in heparinom je možna in vodi do povečanega tveganja za krvavitev.
The use of Clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%). 
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT=43,3 %; IZ: 24,3 %, 57,5 %) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT=18,2 %; IZ: 6,5 %, 28,3 %).
No effect on hepatic metabolising enzymes was observed in humans receiving Clopidogrel at the therapeutic dose. 
Nobenega učinka na presnovne encime niso opazili pri ljudeh ob prejemanju terapevtskih odmerkov.
Patients were randomised to Clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years. 
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali ASA 325 mg/dan, spremljali so jih od 1 do 3 let.
Pharmacogenetics: Based on literature data, patients with genetically reduced CYP2C19 function have lower systemic exposure to the active metabolite of Clopidogrel and diminished antiplatelet responses, and generally exhibit higher cardiovascular event rates following myocardial infarction than do patients with normal CYP2C19 function (see section 5.2). 
Farmakogenetika: Podatki iz literature kažejo, da imajo bolniki z genetsko zmanjšano funkcijo CYP2C19 manjšo sistemsko izpostavljenost aktivnemu presnovku klopidogrela in manjše antitrombocitne odzive; delež kardiovaskularnih dogodkov po miokardnem infarktu je pri teh bolnikih na splošno večji kot pri bolnikih z normalnim delovanjem CYP2C19 (glejte poglavje 5.2).
After single and repeated oral doses of 75 mg per day, Clopidogrel is rapidly absorbed. 
Po enkratnem in večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira.
• If you are allergic (hypersensitive) to Clopidogrel or any of the other ingredients of Clopidogrel 1A Pharma; 
• če ste alergični na (preobčutljivi) na za klopidogrel ali katerokoli sestavino zdravila
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
• bolnikih z akutnim koronarnim sindromom: akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by Clopidogrel. 
Sočasna uporaba heparina ni imela nobenega učinka na inhibicijo agregacije trombocitov, sprožene s klopidogrelom.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of Clopidogrel. 
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
A pharmacodynamic interaction between Clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding. 
Farmakodinamična interakcija med klopidogrelom in acetilsalicilno kislino je možna in vodi do povečanega tveganja za krvavitev.
The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months (Clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (Clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (Clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (Clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (Clopidogrel: 1.9%; placebo: 1.0%). 
Tveganje za krvaviteve (življenje ogrožajoče, velike, manjše, druge) se je zmanjševalo tekom preskušanja: 0 - 1 mesec (klopidogrel: 9,6 %; placebo: 6,6 %), 1 - 3 meseci (klopidogrel: 4,5 %; placebo: 2,3 %), 3 - 6 mesecev (klopidogrel: 3,8 %; placebo: 1,6 %), 6 - 9 mesecev (klopidogrel: 3,2 %; placebo: 1,5 %), 9 - 12 mesecev (klopidogrel: 1,9 %; placebo: 1,0 %).
In vitro and in vivo, Clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
Klopidogrel se in vitro in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa z več encimi citokroma P450.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Take special care with Clopidogrel 1A Pharma'). 
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel 1A Pharma«).
After a single oral dose of 75 mg, Clopidogrel has a half-life of approximately 6 hours. 
Po enem peroralnem odmerku 75 mg je razpolovni čas klopidogrela približno 6 ur.
However, Clopidogrel and ASA have been administered together for up to one year (see section 
Vendar pa so klopidogrel in ASA uporabljali sočasno do enega leta (glejte poglavje 5.1).
The active metabolite of Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni presnovek klopidogrela selektivno zavira vezavo adenozin-difosfata (ADP) na njegov trombocitni receptor P2Y12 in nadaljnjo aktivacijo glikoproteinskega kompleksa GP IIb/IIIa z ADP, s čimer zavre agregacijo trombocitov.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of Clopidogrel and naproxen increased occult gastrointestinal blood loss. 
Nesteroidna protivnetna zdravila (NSAIDs; “Non-Steroidal Anti-Inflammatory Drugs”): v klinični študiji, izvedeni pri zdravih prostovoljcih, je sočasna uporaba klopidogrela in naproksena povečala okultno izgubo krvi iz prebavil.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see sections 4.4 and 5.2). 
Iz previdnosti naj sSočasno o naj ne bi uporabljali zdravil, ki zavirajo CYP2C19 (glejte poglavji 4.4 in 5.2).
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel 1A Pharma'). 
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel 1A
In CURE, the major bleeding event rate for Clopidogrel+ASA was dose-dependent on ASA (< 100 mg: 2.6%; 100-200 mg: 3.5%; >200 mg: 4.9%) as was the major bleeding event rate for placebo+ASA (< 100 mg: 2.0%; 100-200 mg: 2.3%; >200 mg: 4.0%). 
V študiji CURE je bil delež dogodkov z velikimi krvavitvami za klopidogrel in ASA odvisen od odmerka ASA (< 100 mg: 2,6 %; 100 - 200 mg: 3,5 %; > 200 mg: 4,9 %), kakor tudi delež velikih krvavitev za placebo in ASA (< 100 mg: 2,0 %; 100 - 200 mg: 2,3 %; > 200 mg: 4,0 %).
Therefore Clopidogrel should be used with caution in these patients (see section 4.2). 
Zato moramo pri teh bolnikih klopidogrel uporabljati previdno (glejte poglavje 4.2).
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel 1A Pharma (4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja da 300 mg zdravila Klopidogrel 1A Pharma v enkratnem odmerku (štiri 75-mg tablete).
Oral anticoagulants: the concomitant administration of Clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). 
Peroralni antikoagulanti: sočasna uporaba klopidogrela s peroralnimi antikoagulanti ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
Reduced CYP2C19 metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active metabolite by 30-50% following 300- or 600 - mg loading doses and 75 - mg maintenance doses. 
Zmanjšana presnova s CYP2C19 pri srednjih in slabih presnavljalcih je po 300- ali 600-mg polnilnem odmerku in 75-mg vzdrževalnem odmerku zmanjšala
WHAT CLOPIDOGREL 1A PHARMA IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO KLOPIDOGREL 1A PHARMA IN ZA KAJ GA UPORABLJAMO
Mean peak plasma levels of unchanged Clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
Povprečna največja koncentracija nespremenjenega klopidogrela v plazmi (približno 2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
Furthermore, the pharmacodynamic activity of Clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen. 
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala, cimetidina ali estrogena.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p = 0.258]). 
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
Clopidogrel 1A Pharma contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
To zdraviloKlopidogrel 1A Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-Clopidogrel intermediate metabolite. 
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2-oksoklopidogrela.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2). 
Iz previdnosti naj sSočasnoo naj ne bi uporabljali zdravil, ki zavirajo CYP2C19 (za seznam zaviralcev CYP2C19 glejte poglavje 4.5; glejte tudi poglavje 5.2).
As with other antiplatelet agents, Clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. 
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups (0.6% versus 0.5% in the Clopidogrel + ASA and the placebo + ASA groups, respectively). 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah (0,6 % v skupini s klopidogrelom in ASA ter 0,5 % v skupini s placebom in ASA).
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel. 
Iz varnostnih razlogov naj se z dojenjem med zdravljenjem s klopidogremonz zdravilom ne nadaljuje.
CYP2C19*2/*2, *2/*3 or *3/*3 
Slaba presnova: CYP2C19*2/*2, *2/*3 ali *3/*3
HOW TO STORE CLOPIDOGREL 1A PHARMA Store in the original blister in order to protect from moisture. 
SHRANJEVANJE ZDRAVILA KLOPIDOGREL 1A PHARMA Shranjujte v originalnem pretisnem omotu za zagotovitev zaščite pred vlago.
The concomitant administration of Clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5). 
Sočasno dajanje klopidogrela s peroralnimi antikoagulanti se ne priporoča, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
Taking Clopidogrel 1A Pharma with food and drink Clopidogrel 1A Pharma may be taken with or without food. 
Zdravilo Klopidogrel 1A Pharma lahko jemljete s hrano ali brez nje.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that Clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring Clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčnožilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
• very rare: affects less than 1 user in 10,000 
• zelo redki: pojavijo se pri manj kot 1 od 10.000 bolnikov
The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation. 
Učinkoviti tiolov metabolit, ki so ga izolirali in vitro, se hitro in ireverzibilno veže na trombocitne receptorje ter tako zavira agregacijo trombocitov.
Clopidogrel 1A Pharma 75 mg film-coated tablets are white to off-white, marbled, round and biconvex. 
Klopidogrel 1A Pharma 75 mg tablete so bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene tablete.
After repeated doses of 75 mg Clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. 
Po večkratnem odmerjanju 75 mg klopidogrela na dan 10 dni pri bolnikih s hudo okvaro jeter je bilo zavrtje z ADP izzvane agregacije trombocitov podobno kot pri zdravih preiskovancih.
The benefits observed with Clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). 
Koristi, ki so jih opazili s klopidogrelom, so bile neodvisne od drugih akutnih in dolgotrajnih srčnožilnih terapij (kot je heparin /nizkomolekularni heparin, antagonisti glikoproteina IIb/IIIa, učinkovinami za zniževanje lipidov, zaviralci adrenergičnih receptorjev beta in zaviralci angiotenzinske konvertaze (ACEI)).
Esomeprazole is expected to give a similar interaction with Clopidogrel. 
Pričakovati je mogoče, da ima podobno medsebojno delovanje s klopidogrelom tudi esomeprazol.
Clopidogrel 1A Pharma contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel 1A Pharma vsebuje zdravilno učinkovino klopidogrel, ki spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.